Pfizer Corporation

Amgen Fremont Inc.

Bristol-myers Squibb Compnay

Abgenix, Inc.

Other

Pfizer Products Inc.

Ronald P Gladue

Arvind Rajpal

Xiao-Chi Jia

Jose Corvalan

Vahe Bedian

Xiao Feng

Haichun Huang

Brigitte Devaux

Peter Brams

Heidi N Leblanc

Kristopher Toy

Barrett Richard Thiele

Wei Liao

Yi Wu

Yanli Wu

Rory Francis Finn

Timothy J Paradis

Jing Min

Larry L Green

Meina Liang

Bradley T Keller

Shelley Sims Belouski

Shinji Ogawa

Laurie A Tylaska

Laura Cook Blumberg

Matthew Frank Brown

Christopher Stanley Poss

John B Cheng

Jiansu Zhang

Baiyong Li

Kuldeep S Neote

Paul H Bauer

Molly A McGlynn

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Binding molecules to the human OX40 receptor

Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.

Nucleic acids encoding antibodies to CCR2

Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.

Antibodies to CCR2

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses

Nucleic acid molecules which encode antibodies that bind CD40

Antibodies to CD40 and methods of treating cancer and enhancing immune responses

Methods of treating cancer and enhancing immune responses with antibodies that bind CD40

Antibodies to CD40

The present invention relates to the discovery that PDGis the nautral ligand for orphan receptor CRTH2, which interaction, it will now immediately be recognized, is important in the development of valuable pharmaceuticals. The present invention is therefore related to methods for screening for therapeutic compounds useful in the treatment of PGD-related disorders such as allergy, asthma and inflammation. Appropriate assay methodology is also disclosed.

Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2

Piperazine derivatives

Growing community of inventors

Stonington, CT, United States of America

Ronald P Gladue